Stock GNTA GENENTA SCIENCE S.P.A.
Add to a list
To use this feature you must be a member
Log inSign up

Genenta Science S.p.A.

Equities

GNTA

US36870W1009

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
2.59 USD -11.12% Intraday chart for Genenta Science S.p.A. -33.61% -47.68%
Apr. 08 Genenta Science S.P.A. Announces Resignation of Board Members CI
Mar. 29 Genenta Science S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about Genenta Science S.p.A.

Genenta Science S.P.A. Announces Resignation of Board Members CI
Genenta Science S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Genenta Science Demonstrated Reprogramming of the Tumor Microenvironment in Gbm Patients, Paving the Way for Innovative Treatments of Solid Tumors CI
Sandoz to Acquire Cimerli Business from Coherus for $170 Million DJ
Genenta Science S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments CI
Health Care Stocks Support American Depositary Receipts of European Equities MT
Genenta Science S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Genenta Science S.p.A. Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications CI
Genenta Science Says Temferon Receives US FDA's Orphan Drug Designation for Treatment of Glioblastoma Multiforme MT
Genenta Gets FDA Orphan-Drug Designation for Temferon in Glioblastoma Multiforme DJ
FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme CI
HC Wainwright Reiterates Genenta Science S.p.A at Buy With $25 Price Target MT
Genenta Science Signs Development, Manufacturing Deal With AGC Biologics MT
EF Hutton Starts Genenta Science at Buy With $15 Price Target MT
Genenta Science S.P.A. and Ospedale San Raffaele S.R.L. Enters into License Agreement CI
Genenta Science S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Genenta Science S.p.A Shares Plunge After HC Wainwright Initiates Coverage MT
HC Wainwright Initiates Genenta Science at Buy with $25 Price Target MT
Certain Ordinary Shares of Genenta Science S.p.A. are subject to a Lock-Up Agreement Ending on 14-JUN-2022. CI
European ADRs Move Higher in Tuesday Trading MT
European ADRs Decline in Wednesday Trading MT
Genenta Science S.P.A. Announces Ongoing Trial of Temferon™ CI
Genenta Science Announces Preliminary Findings from its Phase 1/2A of Temferon™ in the Treatment of Patients with Glioblastoma CI
Genenta Science S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2021 CI

Chart Genenta Science S.p.A.

Chart Genenta Science S.p.A.
More charts

Company Profile

Genenta Science SpA is an Italy-based company engaged in clinical-stage biotechnology research. The Company focuses on the development of lentivirus-based gene and cell therapies in cancer. It uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The Company not only operates locally but also is present in global markets, including the United States.
Sector
Biotechnology & Medical Research
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.426 EUR
Average target price
21.37 EUR
Spread / Average Target
+780.73%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
GENENTA SCIENCE S.P.A. Stock Genenta Science S.p.A.
-47.68% 47.18M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. GNTA Stock
  4. News Genenta Science S.p.A.
  5. Genenta Science S.p.A Shares Plunge After HC Wainwright Initiates Coverage